CHEPLAPHARM Arzneimittel GmbH launches 100 million EURO investment program

The pharmaceutical firm CHEPLAPHARM Arzneimittel GmbH has embarked on the biggest ever investment program in the history of the company.

This announcement was made on the occasion of a visit by Dr. Arthur König, Lord Mayor of Greifswald, and Dietger Wille, Head of the Municipal Office of Economics and Finance. It is envisaged that the investment - underway since the end of last year - will be dedicated entirely to new products by the end of 2015. "We hope that through the new acquisition, we can achieve a record 100 million turnover this year," the management board of CHEPLAPHARM confidently explained.

CHEPLAPHARM, a company expert in niche products, earned revenues of 61 million EURO during the year 2014 (up 32% over the preceding year). Three-quarters of this revenue was generated from international sales.

CHEPLAPHARM products are sold globally to more than 80 countries. Having taken over New York-based Glenwood LLC in 2014, CHEPLAPHARM also established a presence for its specialty and niche products on the world’s largest pharmaceutical market. Other acquisitions in recent years, including the STREPTOSIL® anti-infective medication from Boehringer Ingelheim or the rights secured from UCB for antihypertensive drugs, have also helped place this young and dynamic pharmaceutical firm on the road to success. For this year, the course is set: “We have the chance to put more into our product pipeline, strengthen market share and build a broader international presence,” explained the management board. “Last year, with the construction of new premises in Ziegelhof and the purchase of the distribution on Riems, we put in place infrastructure as a basis for new growth. Now, with financing in place, we have paved the way for more acquisitions and further growth.”

This record investment program is not being financed by subsidies or grants of any kind. For years, CHEPLAPHARM has enjoyed the trust and support of its key lenders: Deutsche Bank AG, Deutschen Zentral-Genossenschaftsbank AG and HypoVereinsbank AG. These three banks account for the majority of new financing for these acquisitions, thus making a very important contribution.